Cerebral venous thrombosis
ICD-10 I67.6 · ICD-11 8B22.1
What Is the Treatment of Cerebral Venous Thrombosis? First-Line Protocol
Clinical Scenario
Cerebral venous thrombosis (CVT) is a cerebrovascular condition requiring prompt, structured anticoagulation. This protocol covers the evidence-based first-line management approach, aligned with current international guidelines.
Treatment Approach
First-line management begins with parenteral anticoagulation. Once the patient demonstrates clinical and imaging stability, treatment transitions to an oral anticoagulant — the choice of agent and the duration of therapy depend on the underlying aetiology and individual risk profile. The full regimen, sequencing, and decision algorithm are in the structured protocol below.
References
DOI: 10.1161/STR.0000000000000456
- Initiate parenteral anticoagulation — subcutaneous low-molecular-weight heparin (preferred) or unfractionated intravenous heparin.
- Clinical/imaging stability in CVT should prompt transition to an oral anticoagulant.
- Duration of oral anticoagulation depends on the etiology: 3–12 months for transient predisposing factors; high-risk thrombophilia or recurrent VTE: indefinite anticoagulation.
- Previous American Heart Association/American Stroke Association and European guidelines for the management of CVT recommend the initial use of low-molecular-weight heparin over unfractionated heparin followed by transition to oral anticoagulation, with duration determined by the underlying risk profile.